Evidence Report: Parkinson's Disease, Multiple Sclerosis, and Commercial Motor Vehicle Driver Safety (Comprehensive Review)
i


Evidence Report: Parkinson's Disease, Multiple Sclerosis, and Commercial Motor Vehicle Driver Safety (Comprehensive Review)

  • Published Date:

    2009-06-03

  • Language:
    English
Filetype[PDF-2.39 MB]


Details:
  • Alternative Title:
    Parkinson's disease, multiple sclerosis, and commercial motor vehicle driver safety (Comprehensive review)
  • Corporate Creators:
  • Corporate Contributors:
  • Resource Type:
  • Abstract:
    Of all occupations in the United States, workers in the trucking industry experience the third highest fatality rate, accounting for 12% of all worker deaths. About two-thirds of fatally injured truck workers were involved in highway crashes. According to statistics from the U.S. Department of Transportation (DOT), there were 4,932 fatal crashes involving a large truck in 2005 for a total of 5,212 fatalities. In addition, there were 137,144 nonfatal crashes; 59,405 of these were crashes that resulted in an injury to at least one individual (for a total of 89,681 injuries). The purpose of this evidence report is to address several key questions posed by the Federal Motor Carrier Safety Administration (FMCSA). Each of these key questions was developed by the FMCSA such that the answers to these questions provided information that would be useful in updating its current medical examination guidelines. The five key questions addressed in this evidence report are as follows: Key Question 1: What are the criteria that define when an individual with Parkinson’s disease (PD) should stop driving a CMV? Key Question 2: What is the impact of pharmacotherapy for PD on driver safety? Key Question 3: Are individuals with multiple sclerosis (MS) at an increased risk for a motor vehicle crash? If so, what factors associated with MS are predictive of an increased crash risk? Key Question 4: How frequently should individuals with MS be assessed in order to monitor whether they remain safe to drive? Key Question 5: What is the impact of pharmacotherapy for MS on driver safety?
  • Format:
  • Main Document Checksum:
  • File Type:
  • Supporting Files:
    No Additional Files
No Related Documents.

You May Also Like:

Version 3.15